BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 31378204)

  • 1. Pharmacological inhibition of ABCC3 slows tumour progression in animal models of pancreatic cancer.
    Adamska A; Domenichini A; Capone E; Damiani V; Akkaya BG; Linton KJ; Di Sebastiano P; Chen X; Keeton AB; Ramirez-Alcantara V; Maxuitenko Y; Piazza GA; De Laurenzi V; Sala G; Falasca M
    J Exp Clin Cancer Res; 2019 Aug; 38(1):312. PubMed ID: 31378204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ABCC3 is a novel target for the treatment of pancreatic cancer.
    Adamska A; Ferro R; Lattanzio R; Capone E; Domenichini A; Damiani V; Chiorino G; Akkaya BG; Linton KJ; De Laurenzi V; Sala G; Falasca M
    Adv Biol Regul; 2019 Aug; 73():100634. PubMed ID: 31053501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical validation of 3-phosphoinositide-dependent protein kinase 1 inhibition in pancreatic cancer.
    Emmanouilidi A; Fyffe CA; Ferro R; Edling CE; Capone E; Sestito S; Rapposelli S; Lattanzio R; Iacobelli S; Sala G; Maffucci T; Falasca M
    J Exp Clin Cancer Res; 2019 May; 38(1):191. PubMed ID: 31088502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of resistance to FAK inhibition in pancreatic cancer is linked to stromal depletion.
    Jiang H; Liu X; Knolhoff BL; Hegde S; Lee KB; Jiang H; Fields RC; Pachter JA; Lim KH; DeNardo DG
    Gut; 2020 Jan; 69(1):122-132. PubMed ID: 31076405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma.
    Xie Y; Zhu S; Zhong M; Yang M; Sun X; Liu J; Kroemer G; Lotze M; Zeh HJ; Kang R; Tang D
    Gastroenterology; 2017 Nov; 153(5):1429-1443.e5. PubMed ID: 28764929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. JTC801 Induces pH-dependent Death Specifically in Cancer Cells and Slows Growth of Tumors in Mice.
    Song X; Zhu S; Xie Y; Liu J; Sun L; Zeng D; Wang P; Ma X; Kroemer G; Bartlett DL; Billiar TR; Lotze MT; Zeh HJ; Kang R; Tang D
    Gastroenterology; 2018 Apr; 154(5):1480-1493. PubMed ID: 29248440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cotargeting of MEK and PDGFR/STAT3 Pathways to Treat Pancreatic Ductal Adenocarcinoma.
    Sahu N; Chan E; Chu F; Pham T; Koeppen H; Forrest W; Merchant M; Settleman J
    Mol Cancer Ther; 2017 Sep; 16(9):1729-1738. PubMed ID: 28619758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer.
    Yamamoto K; Tateishi K; Kudo Y; Hoshikawa M; Tanaka M; Nakatsuka T; Fujiwara H; Miyabayashi K; Takahashi R; Tanaka Y; Ijichi H; Nakai Y; Isayama H; Morishita Y; Aoki T; Sakamoto Y; Hasegawa K; Kokudo N; Fukayama M; Koike K
    Oncotarget; 2016 Sep; 7(38):61469-61484. PubMed ID: 27528027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Raloxifene inhibits pancreatic adenocarcinoma growth by interfering with ERβ and IL-6/gp130/STAT3 signaling.
    Pozios I; Seel NN; Hering NA; Hartmann L; Liu V; Camaj P; Müller MH; Lee LD; Bruns CJ; Kreis ME; Seeliger H
    Cell Oncol (Dordr); 2021 Feb; 44(1):167-177. PubMed ID: 32940862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of GLI Underlies a Role for BET Bromodomains in Pancreatic Cancer Growth and the Tumor Microenvironment.
    Huang Y; Nahar S; Nakagawa A; Fernandez-Barrena MG; Mertz JA; Bryant BM; Adams CE; Mino-Kenudson M; Von Alt KN; Chang K; Conery AR; Hatton C; Sims RJ; Fernandez-Zapico ME; Wang X; Lillemoe KD; Fernández-Del Castillo C; Warshaw AL; Thayer SP; Liss AS
    Clin Cancer Res; 2016 Aug; 22(16):4259-70. PubMed ID: 27169995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GPR55 signalling promotes proliferation of pancreatic cancer cells and tumour growth in mice, and its inhibition increases effects of gemcitabine.
    Ferro R; Adamska A; Lattanzio R; Mavrommati I; Edling CE; Arifin SA; Fyffe CA; Sala G; Sacchetto L; Chiorino G; De Laurenzi V; Piantelli M; Sansom OJ; Maffucci T; Falasca M
    Oncogene; 2018 Dec; 37(49):6368-6382. PubMed ID: 30061636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inverse Correlation of STAT3 and MEK Signaling Mediates Resistance to RAS Pathway Inhibition in Pancreatic Cancer.
    Nagathihalli NS; Castellanos JA; Lamichhane P; Messaggio F; Shi C; Dai X; Rai P; Chen X; VanSaun MN; Merchant NB
    Cancer Res; 2018 Nov; 78(21):6235-6246. PubMed ID: 30154150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Duffy antigen receptor for chemokines (DARC) expressing in cancer cells inhibits tumor progression by suppressing CXCR2 signaling in human pancreatic ductal adenocarcinoma.
    Maeda S; Kuboki S; Nojima H; Shimizu H; Yoshitomi H; Furukawa K; Miyazaki M; Ohtsuka M
    Cytokine; 2017 Jul; 95():12-21. PubMed ID: 28214673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of MRP4/ABCC4 as a Target for Reducing the Proliferation of Pancreatic Ductal Adenocarcinoma Cells by Modulating the cAMP Efflux.
    Carozzo A; Yaneff A; Gómez N; Di Siervi N; Sahores A; Diez F; Attorresi AI; Rodríguez-González Á; Monczor F; Fernández N; Abba M; Shayo C; Davio C
    Mol Pharmacol; 2019 Jul; 96(1):13-25. PubMed ID: 31043460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibiting YAP expression suppresses pancreatic cancer progression by disrupting tumor-stromal interactions.
    Jiang Z; Zhou C; Cheng L; Yan B; Chen K; Chen X; Zong L; Lei J; Duan W; Xu Q; Li X; Wang Z; Ma Q; Ma J
    J Exp Clin Cancer Res; 2018 Mar; 37(1):69. PubMed ID: 29587800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. UBL4A inhibits autophagy-mediated proliferation and metastasis of pancreatic ductal adenocarcinoma via targeting LAMP1.
    Chen H; Li L; Hu J; Zhao Z; Ji L; Cheng C; Zhang G; Zhang T; Li Y; Chen H; Pan S; Sun B
    J Exp Clin Cancer Res; 2019 Jul; 38(1):297. PubMed ID: 31288830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy.
    Reader CS; Vallath S; Steele CW; Haider S; Brentnall A; Desai A; Moore KM; Jamieson NB; Chang D; Bailey P; Scarpa A; Lawlor R; Chelala C; Keyse SM; Biankin A; Morton JP; Evans TJ; Barry ST; Sansom OJ; Kocher HM; Marshall JF
    J Pathol; 2019 Nov; 249(3):332-342. PubMed ID: 31259422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.
    Wong MH; Xue A; Julovi SM; Pavlakis N; Samra JS; Hugh TJ; Gill AJ; Peters L; Baxter RC; Smith RC
    Clin Cancer Res; 2014 Aug; 20(15):4047-58. PubMed ID: 24895459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Marker-free lineage tracing reveals an environment-instructed clonogenic hierarchy in pancreatic cancer.
    Lodestijn SC; Miedema DM; Lenos KJ; Nijman LE; Belt SC; El Makrini K; Lecca MC; Waasdorp C; van den Bosch T; Bijlsma MF; Vermeulen L
    Cell Rep; 2021 Oct; 37(3):109852. PubMed ID: 34686335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pancreatic stellate cell secreted IL-6 stimulates STAT3 dependent invasiveness of pancreatic intraepithelial neoplasia and cancer cells.
    Nagathihalli NS; Castellanos JA; VanSaun MN; Dai X; Ambrose M; Guo Q; Xiong Y; Merchant NB
    Oncotarget; 2016 Oct; 7(40):65982-65992. PubMed ID: 27602757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.